For Our Colleagues at SIOP
Resources for Professionals and Referring Providers
Pediatric Oncology Observership Program
Children's Hospital of Philadelphia's (CHOP) Global Pediatric Education program offers opportunities to learn in person alongside CHOP’s Cancer Center team. Learn more about clinical observerships and indicate your interest in programs as we restart in-person learning opportunities.
Contact Global Patient Services
The Global Patient Services team at CHOP specializes in providing children around the world access to the most skilled specialists in pediatric medicine and making a family's experience with our Hospital as easy, comfortable and supportive as possible. Call us at 001-267-426-6298 or refer a patient online.
Online Education
Clinical Pathways
Our Clinical Pathways Program aims to incorporate evidence, best practice, and local expert consensus into easily accessible, shared mental models for use by clinical teams at the point of care to facilitate the delivery of high quality medical care.
CHOP Online Pediatric Education Network (OPEN)
CHOP OPEN provides pediatric medical education to healthcare professionals from around the world. Register to access free online lectures, including 50+ presentations in hematology-oncology and hundreds more in various pediatric subspecialties.
Featured lectures
- Evaluation and Management of Thyroid Nodules and Thyroid Cancer in 2022
- Pancreatic Tumors in Childhood
Recent news
- Emily Whitehead, First Pediatric Patient to Receive CAR T-Cell Therapy, Celebrates Cure 10 Years Later
- FDA Approves Drug for Rare Cancer
- FDA Approves First Potentially Curative Gene Therapy for Beta Thalassemia
Highlighted programs and services
Cancer Immunotherapy Program
Children with certain cancers and other disorders of the blood and immune system may benefit from cellular immunotherapy at Children’s Hospital of Philadelphia (CHOP). Doctors at Children's Hospital were the first to begin offering cell therapy in pediatrics as part of a pilot study in 2012. Our doctors and researchers helped develop the first national and international clinical trials for an immunotherapy known as chimeric antigen receptor (“CAR”) T-cell therapy for children with advanced acute lymphoblastic leukemia (ALL). CAR T-cell therapy for B-cell ALL was the first-ever cell therapy to receive FDA approval. Stephan Grupp, MD, PhD, Chief of the Cellular Therapy and Transplant Section at CHOP, was the lead investigator for the global trial led by Novartis.
Learn more about Cancer Immunotherapy Program.
The Center for Precision Medicine for High-Risk Pediatric Cancer
The Center for Precision Medicine for High-Risk Pediatric Cancer is a unified “single stop” for children, adolescents and young adults whose cancers lack an effective standard of care, fail to respond to standard therapy or relapse after initial therapy. The center focuses on comprehensive multi-omics profiling of each patient’s tumor to define the best treatment options for that patient. We utilize state-of-the-art next-generation sequencing and other omics platforms performed in the Division of Genomic Diagnostics’s cancer genomics lab to evaluate the genetic changes that drive the cancer. We integrate this tumor profiling with individual patient and tumor characteristics and any prior treatment to find a personalized treatment strategy.
Learn more about the Center for Precision Medicine for High-Risk Pediatric Cancer.
Comprehensive Vascular Anomalies Program (CVAP)
Patients with vascular anomalies have conditions of the veins, arteries and the lymphatic system that can be classified as tumors (benign and malignant) and vascular malformations (congenital anomalies of the vasculature). These conditions, which can range in complexity, can cause pronounced visible deformities and disfigurement, impede critical organ functions such as swallowing or breathing, or cause severe pain interfering with one’s quality of life. The CVAP at Children’s Hospital of Philadelphia (CHOP) includes state-of-the-art genomics and personalized research strategies to determine the causes of these conditions and identify targeted therapies. These innovative options are based on standards of excellent interdisciplinary clinical care.
Very Rare Malignant Tumors Program
Children with very rare malignant tumors will find unparalleled expertise in the multidisciplinary team at the Very Rare Malignant Tumors Program. These tumors come in different forms and are individually very rare, but as an aggregate, they comprise more than 10% of all pediatric cancers. Our program will give these patients a pediatric medical home and also drive discoveries in these often under-researched types of cancers.
Learn more about Very Rare Malignant Tumors Program.
Pediatric Thyroid Center
The Pediatric Thyroid Center is dedicated to the unique medical needs of children, adolescents and teens with thyroid disease, including thyroid cancer. Our center provides the ideal combination of experience and resources, so we can provide individualized care for children.
Learn more about the Pediatric Thyroid Center.
Refractory Neuroblastoma Program
The Refractory Neuroblastoma Program offers exceptional personalized care to children with refractory (relapsed) neuroblastoma, including treatment with unique therapies. As an established program with an excellent reputation, we receive referrals from around the world and treat a large volume of cases.
Learn more about the Refractory Neuroblastoma Program.
Clinical trials
The Cancer Center is a world leader in clinical research and trials. View some of our highlighted studies and trials.
Additional resources
- Subscribe to CHOP’s International Update
- More Information about the Cancer Center
- Center for Childhood Cancer Research
- More Cancer Center Resources for Professionals